Caveolae: One Function or Many?

Trends in Cell Biology

Volumn 26, Issue 3, 2016, Pages 177-189

  Cheng, Jade P X ^a   Nichols, Benjamin J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Caveolae; Caveolin; Cavin; Endocytosis; Mechanoprotection; Transcytosis

Indexed keywords

CARDIOMYOPATHY; CAVEOLA; CELL FUNCTION; DIET INDUCED OBESITY; ENDOCYTOSIS; FIBROSING ALVEOLITIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; GLUCOSE INTOLERANCE; HEART ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID HOMEOSTASIS; LIPODYSTROPHY; LUNG ALVEOLUS WALL; MUSCLE HYPERTROPHY; MUSCULAR DYSTROPHY; MYOPATHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCYTOSIS; ANIMAL; LIPID METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT;

CAVEOLIN;

ANIMALS; CAVEOLAE; CAVEOLINS; ENDOCYTOSIS; HUMANS; LIPID METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84958106156     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.10.010     Document Type: Review

References (162)

1. Palade G.E. Fine structure of blood capillaries. J. Appl. Phys. 1953, 24:1424.
2. Rothberg K.G., et al. Caveolin, a protein component of caveolae membrane coats. Cell 1992, 68:673-682.
3. Kovtun O., et al. Cavin family proteins and the assembly of caveolae. J. Cell Sci. 2015, 128:1269-1278.
4. Kovtun O., et al. Structural insights into the organization of the cavin membrane coat complex. Dev. Cell 2014, 31:405-419.
5. Way M., Parton R.G. M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett. 1996, 378:108-112.
6. Tang Z., et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem. 1996, 271:2255-2261.
7. Scherer P.E., et al. Identification, sequence, and expression of caveolin-defines a caveolin gene family. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:131-135.
8. Liu L., et al. Deletion of cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 2008, 8:310-317.
9. Hill M.M., et al. PTRF-cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008, 132:113-124.
10. Vinten J., et al. Identification of a major protein on the cytosolic face of caveolae. Biochim. Biophys. Acta 2005, 1717:34-40.
11. Aboulaich N., et al. Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes. Biochem. J. 2004, 383:237-248.
12. Vinten J., et al. A 60-kDa protein abundant in adipocyte caveolae. Cell Tissue Res. 2001, 305:99-106.
13. Bastiani M., et al. MURC/cavin-and cavin family members form tissue-specific caveolar complexes. J. Cell Biol. 2009, 185:1259-1273.
14. McMahon K.A., et al. SRBC/cavin-is a caveolin adapter protein that regulates caveolae function. EMBO J. 2009, 28:1001-1015.
15. Hansen C.G., Nichols B.J. Molecular mechanisms of clathrin-independent endocytosis. J. Cell Sci. 2009, 122:1713-1721.
16. Davalos A., et al. Quantitative proteomics of caveolin-1-regulated proteins: characterization of polymerase I and transcript release factor/cavin-in endothelial cells. Mol. Cell. Proteomics 2010, 9:2109-2124.
17. Hayer A., et al. Biogenesis of caveolae: stepwise assembly of large caveolin and cavin complexes. Traffic 2009, 11:361-382.
18. Liu L., Pilch P.F. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J. Biol. Chem. 2008, 283:4314-4322.
19. Ludwig A., et al. Molecular composition and ultrastructure of the caveolar coat complex. PLoS Biol. 2013, 11:e1001640.
20. Gambin Y., et al. Single-molecule analysis reveals self assembly and nanoscale segregation of two distinct cavin subcomplexes on caveolae. Elife 2013, 3:e01434.
21. Zhao Y.Y., et al. Defects in caveolin-cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11375-11380.
22. Razani B., et al. Caveolin-null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 2001, 276:38121-38138.
23. Drab M., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-gene-disrupted mice. Science 2001, 293:2449-2452.
24. Parton R.G., Richards A.A. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 2003, 4:724-738.
25. Nichols B. Caveosomes and endocytosis of lipid rafts. J. Cell Sci. 2003, 116:4707-4714.
26. Pelkmans L., Helenius A. Endocytosis via caveolae. Traffic 2002, 3:311-320.
27. Mohan J., et al. Cavin3 interacts with cavin1 and caveolin1 to increase surface dynamics of caveolae. J. Cell Sci. 2015, 128:979-991.
28. Liu L., et al. Cavin-knockout mice show that cavin-is not essential for caveolae formation, for maintenance of body composition, or for glucose tolerance. PLoS ONE 2014, 9:e102935.
29. Hansen C.G., et al. Pacsin 2 is recruited to caveolae and functions in caveolar biogenesis. J. Cell Sci. 2011, 124:2777-2785.
30. Koch D., et al. Ultrastructural freeze-fracture immunolabeling identifies plasma membrane-localized syndapin II as a crucial factor in shaping caveolae. Histochem. Cell Biol. 2012, 138:215-230.
31. Yao Q., et al. Caveolin-interacts directly with dynamin-2. J. Mol. Biol. 2005, 348:491-501.
32. Oh P., et al. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 1998, 141:101-114.
33. Henley J.R., et al. Dynamin-mediated internalization of caveolae. J. Cell Biol. 1998, 141:85-99.
34. Stoeber M., et al. Oligomers of the ATPase EHD2 confine caveolae to the plasma membrane through association with actin. EMBO J. 2012, 31:2350-2364.
35. Moren B., et al. EHD2 regulates caveolar dynamics via ATP-driven targeting and oligomerization. Mol. Biol. Cell 2012, 23:1316-1329.
36. Kostan J., et al. Direct interaction of actin filaments with F-BAR protein pacsin2. EMBO Rep. 2014, 15:1154-1162.
37. Senju Y., et al. Essential role of PACSIN2/syndapin-II in caveolae membrane sculpting. J. Cell Sci. 2011, 124:2032-2040.
38. Parton R.G. Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem. 1994, 42:155-166.
39. Nichols B.J., et al. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J. Cell Biol. 2001, 153:529-541.
40. Orlandi P.A., Fishman P.H. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J. Cell Biol. 1998, 141:905-915.
41. Pelkmans L., et al. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 2001, 3:473-483.
42. Hayer A., et al. Caveolin-is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J. Cell Biol. 2010, 191:615-629.
43. Engel S., et al. Role of endosomes in simian virus 40 entry and infection. J. Virol. 2011, 85:4198-4211.
44. Parton R.G., Howes M.T. Revisiting caveolin trafficking: the end of the caveosome. J. Cell Biol. 2010, 191:439-441.
45. Torgersen M.L., et al. Internalization of cholera toxin by different endocytic mechanisms. J. Cell Sci. 2001, 114:3737-3747.
46. Nichols B.J. A distinct class of endosome mediates clathrin-independent endocytosis to the Golgi complex. Nat. Cell Biol. 2002, 4:374-378.
47. Hansen G.H., et al. Cholera toxin entry into pig enterocytes occurs via a lipid raft- and clathrin-dependent mechanism. Biochemistry 2005, 44:873-882.
48. Damm E.M., et al. Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J. Cell Biol. 2005, 168:477-488.
49. Ewers H., et al. Single-particle tracking of murine polyoma virus-like particles on live cells and artificial membranes. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15110-15115.
50. Romer W., et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007, 450:670-675.
51. Shvets E., et al. Dynamic caveolae exclude bulk membrane proteins and are required for sorting of excess glycosphingolipids. Nat. Commun. 2015, 6:6867.
52. Kirkham M., et al. Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. J. Cell Biol. 2005, 168:465-476.
53. Thomsen P., et al. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol. Biol. Cell 2002, 13:238-250.
54. Bitsikas V., et al. Clathrin-independent pathways do not contribute significantly to endocytic flux. Elife 2014, 3:e03970.
55. Lobo S., Bernlohr D.A. Fatty acid transport in adipocytes and the development of insulin resistance. Novartis Found. Symp. 2007, 286:113-121. discussion 121-126, 162-163, 196-203.
56. Ring A., et al. Caveolin-is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. Biochim. Biophys. Acta 2006, 1761:416-423.
57. Meshulam T., et al. Role of caveolin-and cholesterol in transmembrane fatty acid movement. Biochemistry 2006, 45:2882-2893.
58. Souto R.P., et al. Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signaling. J. Biol. Chem. 2003, 278:18321-18329.
59. Demir K., et al. RAB8B is required for activity and caveolar endocytosis of LRP6. Cell Rep. 2013, 4:1224-1234.
60. Yamamoto H., et al. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of β-catenin signaling. Dev. Cell 2008, 15:37-48.
61. Lajoie P., Nabi I.R. Regulation of raft-dependent endocytosis. J. Cell. Mol. Med. 2007, 11:644-653.
62. Le P.U., et al. Caveolin-is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J. Biol. Chem. 2002, 277:3371-3379.
63. Chaudhary N., et al. Endocytic crosstalk: cavins, caveolins, and caveolae regulate clathrin-independent endocytosis. PLoS Biol. 2014, 12:e1001832.
64. Vasile E., et al. Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J. Cell Biol. 1983, 96:1677-1689.
65. Nistor A., Simionescu M. Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. Am. Rev. Respir. Dis. 1986, 134:1266-1272.
66. Ghitescu L., et al. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis. J. Cell Biol. 1986, 102:1304-1311.
67. Bendayan M., Rasio E.A. Transport of insulin and albumin by the microvascular endothelium of the rete mirabile. J. Cell Sci. 1996, 109:1857-1864.
68. Milici A.J., et al. Transcytosis of albumin in capillary endothelium. J. Cell Biol. 1987, 105:2603-2612.
69. Peters K.R., et al. Endothelial plasmalemmal vesicles have a characteristic striped bipolar surface structure. J. Cell Biol. 1985, 101:2233-2238.
70. Ogawa K., et al. Caveolar and intercellular channels provide major transport pathways of macromolecules across vascular endothelial cells. Anat. Rec. 2001, 264:32-42.
71. Rosengren B.I., et al. Transvascular protein transport in mice lacking endothelial caveolae. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1371-H1377.
72. Rippe B., et al. Transendothelial transport: the vesicle controversy. J. Vasc. Res. 2002, 39:375-390.
73. -/- knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-null mice. J. Biol. Chem. 2002, 277:40091-40098.
74. Hansen C.G., et al. Deletion of cavin genes reveals tissue-specific mechanisms for morphogenesis of endothelial caveolae. Nat. Commun. 2013, 4:1831.
75. Oh P., et al. In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors. Nat. Med. 2014, 20:1062-1068.
76. Oh P., et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 2007, 25:327-337.
77. Chang S.H., et al. Vascular permeability and pathological angiogenesis in caveolin-1-null mice. Am. J. Pathol. 2009, 175:1768-1776.
78. Kohn S., et al. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab. Invest. 1992, 67:596-607.
79. Dvorak A.M., et al. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukoc. Biol. 1996, 59:100-115.
80. Dvorak A.M., Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem. 2001, 49:419-432.
81. Kim C.A., et al. Association of a homozygous nonsense caveolin-mutation with Berardinelli-Seip congenital lipodystrophy. J. Clin. Endocrinol. Metab. 2008, 93:1129-1134.
82. Pilch P.F., Liu L. Fat caves: caveolae, lipid trafficking and lipid metabolism in adipocytes. Trends Endocrinol. Metab. 2011, 22:318-324.
83. Rajab A., et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010, 6:e1000874.
84. Ariotti N., et al. Caveolae regulate the nanoscale organization of the plasma membrane to remotely control Ras signaling. J. Cell Biol. 2014, 204:777-792.
85. Prior I.A., et al. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J. Cell Biol. 2003, 160:165-170.
86. Le Lay S., Kurzchalia T.V. Getting rid of caveolins: phenotypes of caveolin-deficient animals. Biochim. Biophys. Acta 2005, 1746:322-333.
87. Kirkham M., et al. Evolutionary analysis and molecular dissection of caveola biogenesis. J. Cell Sci. 2008, 121:2075-2086.
88. Parker S., et al. Caveolin-is required for apical lipid trafficking and suppresses basolateral recycling defects in the intestine of Caenorhabditis elegans. Mol. Biol. Cell 2009, 20:1763-1771.
89. Siddiqi S., et al. Intestinal caveolin-is important for dietary fatty acid absorption. Biochim. Biophys. Acta 2013, 1831:1311-1321.
90. Mundy D.I., et al. Caveolin targeting to late endosome/lysosomal membranes is induced by perturbations of lysosomal pH and cholesterol content. Mol. Biol. Cell 2012, 23:864-880.
91. Yamamoto H., et al. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of β-catenin. Dev. Cell 2006, 11:213-223.
92. Repetto S., et al. Insulin and IGF-phosphorylate eNOS in HUVECs by a caveolin-dependent mechanism. Biochem. Biophys. Res. Commun. 2005, 337:849-852.
93. Saltiel A.R., Pessin J.E. Insulin signaling in microdomains of the plasma membrane. Traffic 2003, 4:711-716.
94. Lin D., et al. Protein kinase Cγ regulation of gap junction activity through caveolin-1-containing lipid rafts. Invest. Ophthalmol. Vis. Sci. 2003, 44:5259-5268.
95. Karlsson M., et al. Insulin induces translocation of glucose transporter GLUT4 to plasma membrane caveolae in adipocytes. FASEB J. 2002, 16:249-251.
96. Nystrom F.H., et al. Caveolin-interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-cells and rat adipose cells. Mol. Endocrinol. 1999, 13:2013-2024.
97. Gustavsson J., et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 1999, 13:1961-1971.
98. Couet J., et al. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 1997, 272:30429-30438.
99. Shaul P.W., et al. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 1996, 271:6518-6522.
100. Gustavsson J., et al. Insulin-stimulated glucose uptake involves the transition of glucose transporters to a caveolae-rich fraction within the plasma membrane: implications for type II diabetes. Mol. Med. 1996, 2:367-372.
101. Garcia-Cardena G., et al. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:6448-6453.
102. Li S., et al. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 1996, 271:29182-29190.
103. Michel J.B., et al. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J. Biol. Chem. 1997, 272:25907-25912.
104. Venema V.J., et al. Interaction of neuronal nitric-oxide synthase with caveolin-in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J. Biol. Chem. 1997, 272:28187-28190.
105. Sowa G., et al. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14072-14077.
106. Kolluru G.K., et al. eNOS phosphorylation in health and disease. Biochimie 2010, 92:1186-1198.
107. Tousoulis D., et al. The role of nitric oxide on endothelial function. Curr. Vasc. Pharmacol. 2012, 10:4-18.
108. Zhao Y.Y., et al. Persistent eNOS activation secondary to caveolin-deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J. Clin. Invest. 2009, 119:2009-2018.
109. Budhiraja R., et al. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-165.
110. Collins B.M., et al. Structure-based reassessment of the caveolin signaling model: do caveolae regulate signaling through caveolin-protein interactions?. Dev. Cell 2012, 23:11-20.
111. Byrne D.P., et al. Evaluating caveolin interactions: do proteins interact with the caveolin scaffolding domain through a widespread aromatic residue-rich motif?. PLoS ONE 2012, 7:e44879.
112. Trane A.E., et al. Deciphering the binding of caveolin-to client protein endothelial nitric-oxide synthase (eNOS): scaffolding subdomain identification, interaction modeling, and biological significance. J. Biol. Chem. 2014, 289:13273-13283.
113. Wypijewski K.J., et al. Identification of caveolar resident proteins in ventricular myocytes using a quantitative proteomic approach: dynamic changes in caveolar composition following adrenoceptor activation. Mol. Cell. Proteomics 2015, 14:596-608.
114. Dulhunty A.F., Franzini-Armstrong C. The relative contributions of the folds and caveolae to the surface membrane of frog skeletal muscle fibres at different sarcomere lengths. J. Physiol. 1975, 250:513-539.
115. Sinha B., et al. Cells respond to mechanical stress by rapid disassembly of caveolae. Cell 2011, 144:402-413.
116. Gambin Y., et al. Single-molecule analysis reveals self assembly and nanoscale segregation of two distinct cavin subcomplexes on caveolae. Elife 2014, 3:e01434.
117. Gervasio O.L., et al. Caveolae respond to cell stretch and contribute to stretch-induced signaling. J. Cell Sci. 2011, 124:3581-3590.
118. Corrotte M., et al. Caveolae internalization repairs wounded cells and muscle fibers. Elife 2013, 2:e00926.
119. Bernatchez P.N., et al. Myoferlin is critical for endocytosis in endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 297:C484-C492.
120. Cheng J.P.X., et al. Caveolae protect endothelial cells from membrane rupture during increased cardiac output. J. Cell Biol. 2015, 211:53-61.
121. Bauer P.M., et al. Endothelial-specific expression of caveolin-impairs microvascular permeability and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:204-209.
122. Echarri A., Del Pozo M.A. Caveolae - mechanosensitive membrane invaginations linked to actin filaments. J. Cell Sci. 2015, 128:2747-2758.
123. Yang B., Rizzo V. Shear stress activates eNOS at the endothelial apical surface through 1 containing integrins and caveolae. Cell. Mol. Bioeng. 2013, 6:346-354.
124. Joshi B., et al. Phosphocaveolin-is a mechanotransducer that induces caveola biogenesis via Egr1 transcriptional regulation. J. Cell Biol. 2012, 199:425-435.
125. Radel C., et al. Participation of caveolae in β1 integrin-mediated mechanotransduction. Biochem. Biophys. Res. Commun. 2007, 358:626-631.
126. Peng F., et al. RhoA activation in mesangial cells by mechanical strain depends on caveolae and caveolin-interaction. J. Am. Soc. Nephrol. 2007, 18:189-198.
127. Shi F., Sottile J. Caveolin-1-dependent β1 integrin endocytosis is a critical regulator of fibronectin turnover. J. Cell Sci. 2008, 121:2360-2371.
128. Yang B., et al. p190 RhoGTPase-activating protein links the β1 integrin/caveolin-mechanosignaling complex to RhoA and actin remodeling. Arterioscler. Thromb. Vasc. Biol. 2011, 31:376-383.
129. Israeli-Rosenberg S., et al. Caveolin modulates integrin function and mechanical activation in the cardiomyocyte. FASEB J. 2015, 29:374-384.
130. Goetz J.G., et al. Biomechanical remodeling of the microenvironment by stromal caveolin-favors tumor invasion and metastasis. Cell 2011, 146:148-163.
131. del Pozo M.A., et al. Phospho-caveolin-mediates integrin-regulated membrane domain internalization. Nat. Cell Biol. 2005, 7:901-908.
132. Volonte D., et al. Cellular stress induces the tyrosine phosphorylation of caveolin-(Tyr14) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J. Biol. Chem. 2001, 276:8094-8103.
133. McNally E.M., et al. Caveolin-in muscular dystrophy. Hum. Mol. Genet. 1998, 7:871-877.
134. Woodman S.E., et al. Caveolinopathies: mutations in caveolin-cause four distinct autosomal dominant muscle diseases. Neurology 2004, 62:538-543.
135. Hayashi Y.K., et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J. Clin. Invest. 2009, 119:2623-2633.
136. Austin E.D., et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ. Cardiovasc. Genet. 2012, 5:336-343.
137. Briand N., et al. Distinct roles of endothelial and adipocyte caveolin-in macrophage infiltration and adipose tissue metabolic activity. Diabetes 2011, 60:448-453.
138. Govender P., et al. Cavin1; a regulator of lung function and macrophage phenotype. PLoS ONE 2013, 8:e62045.
139. Martin S., et al. Caveolin-deficiency leads to increased susceptibility to cell death and fibrosis in white adipose tissue: characterization of a lipodystrophic model. PLoS ONE 2012, 7:e46242.
140. Woodman S.E., et al. Caveolin-knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J. Biol. Chem. 2002, 277:38988-38997.
141. Hayashi T., et al. Identification and functional analysis of a caveolin-mutation associated with familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 2004, 313:178-184.
142. Cohen A.W., et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am. J. Physiol. Cell Physiol. 2003, 285:C222-C235.
143. -/- mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L865-L873.
144. Wunderlich C., et al. The adverse cardiopulmonary phenotype of caveolin-deficient mice is mediated by a dysfunctional endothelium. J. Mol. Cell. Cardiol. 2008, 44:938-947.
145. Marsboom G., et al. Newly identified caveolin-mutation associated with heritable human pulmonary arterial hypertension mediates hyperproliferation via augmented calcium signaling. FASEB J. 2014, 28(Suppl.). 1089.10.
146. Sward K., et al. Elevated pulmonary arterial pressure and altered expression of Ddah1 and Arg1 in mice lacking cavin-1/PTRF. Physiol. Rep. 2013, 1:e00008.
147. Razani B., et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol. Cell. Biol. 2002, 22:2329-2344.
148. Pfeufer A., et al. Genome-wide association study of PR interval. Nat. Genet. 2010, 42:153-159.
149. Vatta M., et al. Mutant caveolin-induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006, 114:2104-2112.
150. Cronk L.B., et al. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm 2007, 4:161-166.
151. Ardissone A., et al. Novel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy. BMC Med. Genet. 2013, 14:89.
152. Minetti C., et al. Mutations in the caveolin-gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 1998, 18:365-368.
153. Betz R.C., et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat. Genet. 2001, 28:218-219.
154. Vorgerd M., et al. A sporadic case of rippling muscle disease caused by a de novo caveolin-mutation. Neurology 2001, 57:2273-2277.
155. Galbiati F., et al. Caveolin-null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J. Biol. Chem. 2001, 276:21425-21433.
156. Razani B., et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 2002, 277:8635-8647.
157. Ding S.Y., et al. Pleiotropic effects of cavin-deficiency on lipid metabolism. J. Biol. Chem. 2014, 289:8473-8483.
158. Cao H., et al. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis. 2008, 7:3.
159. Dwianingsih E.K., et al. A Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy type 4. Mol. Genet. Metab. 2010, 101:233-237.
160. Shastry S., et al. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am. J. Med. Genet. A 2010, 152A:2245-2253.
161. Briand N., et al. Caveolin-expression and cavin stability regulate caveolae dynamics in adipocyte lipid store fluctuation. Diabetes 2014, 63:4032-4044.
162. Lo H.P., et al. The caveolin-cavin system plays a conserved and critical role in mechanoprotection of skeletal muscle. J. Cell. Biol. 2015, 210:833-849.